Connect with us

International

Top Penny Stocks To Watch As Monkeypox Cases Rise

Monkeypox penny stocks to watch right now
The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News…

Published

on

The latest outbreak of monkeypox has some scratching their heads. What more can 2022 bring to the market? We’ve seen a stock market crash, the hopeful recovery from COVID-19, record inflation, rising rates, and now this. But it has placed some penny stocks in focus.

On Wednesday, the World Health Organization (WHO) confirmed more than 550 monkeypox cases in 30 countries. Now on a global scale, this is the latest virus to strike some fear in the hearts of investors who had to endure the pain of the last pandemic only a few years ago.

One of the main concerns is that not even the WHO knows how to gauge the outbreak. During a press conference this week, monkeypox technical lead Dr. Rosamund Lewis said, “We don’t really know whether it’s too late to contain. What WHO and all member states are trying to do is prevent onward spread.”

Meanwhile, WHO Director-General Tedros Adhanom Ghebreyesus has already tried easing concerns. The Director-General recently explained that the global appearance of monkeypox indicates that it has been spreading undetected for some time out of Africa. Tedros also said that most symptoms generally resolve on their own. Though in some cases, the virus can be more severe.

Monkeypox Stock To Watch

Since there are close ties to the smallpox virus, some looking for opportunities seek stocks of companies working on vaccine candidates. For anyone trading penny stocks, Tonix Pharmaceuticals’ (NASDAQ: TNXP) latest headline shows how news can act as a significant catalyst. Shares were already on the rise following the announcement of a stock buyback plan. On Wednesday, the company also announced the issuance of a patent for its smallpox and monkeypox vaccine, TNX-801.

[Read More] Why These 3 Penny Stocks Climbed Today

Another one of the monkeypox stocks setting a tone in the stock market today is SIGA Technologies (NASDAQ: SIGA). The company’s shares have been moving since traders began following developments of SIGA’s Tpoxx platform for smallpox and its potential application for monkeypox.

Other monkeypox stocks haven’t faired as well as TNXP and SIGA stock. For instance, Bavarian Nordic (OTC: BVNRY) actually obtained orders for its JYNNEOS® smallpox vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA). This would allow for the first doses of this version to be manufactured and invoiced in 2023 and 2024. According to headlines this week, the options have a value of $119 million and “represent the first options exercised to convert bulk vaccine…into freeze-dried doses of JYNNEOS smallpox vaccine.”

Despite this as the case, shares of BVNRY stock haven’t reacted as positively in the stock market. In fact, since May 20th, the stock has dropped from highs of $11.70 to lows of $9.23 this week.

Monkeypox Penny Stocks For Your June Watch List

1. GeoVax Labs, Inc. (NASDAQ: GOVX)

penny stocks to buy Geovax Labs GOVX stock

GeoVax (GOVX Stock Report) develops vaccines and immunotherapies and has been in the spotlight for monkeypox stock hunters over the last few weeks. We discussed it on a late-May list of monkeypox penny stocks to watch. Where the angle comes into play is with GeoVax’s GV-MVA-VLPTM platform. It is used to construct vaccine candidates using genetic sequences from viruses. A statement earlier this year has come back into focus thanks to GeoVax’s Chief Scientific Officer, Farshad Guirakhoo, Ph.D. He said GeoVax’s platform and mentioned smallpox and monkeypox specifically.

[Read More] Hot Penny Stocks to Watch That Are Climbing Right Now

“Perhaps of critical importance is that the viral basis of our vaccine vector (MVA) has more than 50 years of safety records and has been recently approved by the FDA for prevention of smallpox and monkeypox diseases,” Dr. Guirakhoo explained.

The company also recently presented at the Genetic Vaccine Development for Infectious Disease Summit on May 26th. This presentation was made just a few days prior to GeoVax making a Tweet that resonated strongly with the market. The company’s May 31st Tweet said: “Previous peer reviewed publications have validated that the GeoVax constructs of MVA also provide protection against monkeypox.”

Heading into the rest of the short week, GOVX stock could remain one to watch if monkeypox cases continue rising.

2. Chimerix (NASDAQ: CMRX)

penny stocks to buy Chimerix CMRX stock

LIke Bavarian Nordic, Chimerix (CMRX Stock Report) has been muted during this monkeypox explosion in the stock market. One of the reasons for more downbeat than upbeat sentiment is its divestiture of the company’s only marketed product. Emergent BioSolutions Inc. (NYSE: EBS), another one of the monkeypox stocks to watch, purchased exclusive worldwide rights to Chimerix’s Tembexa. This is the first FDA-approved antiviral for all age groups for smallpox.

Thanks to the close connection of the viruses, smallpox stocks are on watch as potential monkeypox vaccine developers. “This transaction expands and further diversifies our medical countermeasures business with the addition of a small molecule therapeutic that aligns with the government’s smallpox preparedness strategy,” said Paul Williams, SVP government/MCM business at Emergent, in a May update.

Part of the deal includes a 20% royalty on future gross profit of Tembexa in the US linked to volumes above 1.7 million treatment courses. Chimerix also said that it could obtain a 15% royalty on all gross profit outside of the US associated with the drug sales in the exclusivity period on a market-to-market basis. Next week the company presents a corporate overview at the Jefferies Healthcare Conference on June 8th.

3. Aethlon Medical, Inc. (NASDAQ: AEMD)

best penny stocks to watch Aethlon Medical (AEMD)

Aethlon’s (AEMD Stock Report) pipeline of treatments is designed to target different organ-threatening diseases. For example, its Hemopurifier has been studied as an active platform to fight future COVID-19 variants that can impact the efficacy of certain vaccines. The device was given Breakthrough Device status in treating patients with metastatic cancer. Furthermore, an Investigational Device Exemption was granted in 2019 for cancer and was also updated to include a clinical study of patients with viral infections, including COVID.

[Read More] How To Make Money With Penny Stocks

Where does monkeypox come into play? Aethlon claims that “pre-clinical Hemopurifier studies have validated the broad-spectrum capture of numerous viral threats. These include: Chikungunya, Dengue and West Nile virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.”

Like the others on this list of penny stocks, more monkeypox headlines could put some of these names on the radar this week.

Final Thoughts

Will monkeypox become as big as COVID? That’s yet to be seen, and so far (thankfully), not the case. However, like in the early days of the pandemic, data is just beginning to come out. Speculation has become a driving force for traders, considering the uncertainty right now. As such, it’s essential to realize this and make sure to develop a proper strategy.

Monkeypox Stocks To Watch

SymbolCompany Name
SIGASIGA Technologies
EBSEmergent Biosolutions Inc.
BVNRYBavarian Nordic
GOVXGeoVax Labs Inc.
TNXPTonix Pharmaceuticals Holding Corp.
CMRXChimerix Inc.
AEMDAethlon Medical Inc.

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Zelensky Departs Washington Mostly Empty-Handed Amid Mood Shift In West

Zelensky Departs Washington Mostly Empty-Handed Amid Mood Shift In West

By all accounts, Zelensky came away from his Washington visit with…

Published

on

Zelensky Departs Washington Mostly Empty-Handed Amid Mood Shift In West

By all accounts, Zelensky came away from his Washington visit with nothing new. Biden did announce a fresh $325 million aid package for Ukraine from already committed funds, but the hoped-for long range missile approval never came (however, more cluster bombs are being sent). And as we detailed Thursday, House Republican leadership once again failed to move forward on a mere procedural vote for the Pentagon funding bill, due in large part to GOP members rejecting Biden's proposed $24 billion more in Ukraine aid.

Thursday's package announced by Biden, as Zelensky visited the White House and Capitol Hill, was run-of-the-mill and entirely to be expected. "Today I approved the next tranche of U.S. security assistance to Ukraine including more artillery, more ammunition, more anti-tank weapons and next week, the first U.S. Abrams tanks will be delivered to Ukraine," Biden said.

As for the earlier in the day (Thurs.) meeting with Congressional leaders, House Speaker Kevin McCarthy explained when asked why the Ukrainian leader's request to address Congress was denied, "Zelensky asked for a joint session, we just didn't have time. He's already given a joint session."

Via AFP

Instead in a closed-door meeting, Zelensky later acknowledged he discussed with lawmakers "the battlefield situation and priority defense needs."

But if there is any level of consolation for Kiev, it's seen in the Pentagon announcement which came late in the day Thursday. Facing potential US government shutdown on Oct.1st, given at this point Congress is not expected to pass the 12 appropriations bills needed to fund government operations before next fiscal year, the Pentagon has said it will exempt its operations supporting Ukraine from a shutdown. 

The military typically suspends any activities not deemed vital to national security during government shutdowns, thus the DoD is in effect saying Ukraine aid remains "vital to national security". 

"Operation Atlantic Resolve is an excepted activity under a government lapse in appropriations," Pentagon spokesman Chris Sherwood told Politico, in reference to the operational name still used for actions supporting Kiev.

But Politico points out a potential shutdown would still negatively impact US support to Ukraine:

Sherwood noted that while DOD’s activities related to Ukraine will continue, furloughs and other activities halted under the shutdown could still have a negative impact.

"Training would happen, but depending on whether or not there were certain personnel that were not able to report for duty, for example, that could have an impact," said Pentagon spokesperson Brig. Gen. Patrick Ryder on Thursday.

This Pentagon exemption to keep Ukraine-related support active during a government shutdown seems to be the only significant thing Zelensky came away with. 

It appears to have been the main object of discussion when Zelensky met with Secretary of Defense Lloyd Austin in Washington during the trip. The Pentagon said this was "to reaffirm the steadfast US support for Ukraine."

Meanwhile, Bloomberg takes note of Zelensky "showing the strain" amid increasing divisions among allies:

The Ukrainian president allowed a dispute with one of his biggest allies to spin out of control at the United Nations General Assembly this week, and that’s just a hint of the tensions building behind the scenes.

Zelenskiy has been leading his country through Russia’s brutal assault for 19 months, all the time fighting on another front to wring the weapons and finance he needs from his US and European supporters. Now he suspects that President Joe Biden’s commitment is wavering and other leaders may be taking their cue from the US, according to a person who met with him recently.

He grew very emotional at times during that discussion, the person said, and was scathing in his criticism of nations that he said weren’t delivering weapons quickly enough.

Washington's lackluster greeting of Zelensky this week (compared to how he was received in December 2022) came simultaneous to Poland declaring it will no longer arm Ukraine, amid a fierce diplomatic spat over blockage of Ukraine grain imports by Warsaw, to protect Polish farmers.

The Economist is also taking note of the significant mood shift among Western allies...

A "long war" indeed... given a G7 leader from a European country has told reporters this week that the West is prepared for a years-long war, something likely to last some six or seven years, according to the quote.

"A senior official from one European G-7 country said the war may last as much as six or seven more years and that allies need to plan financially to continue support for Kyiv for such a long conflict," Bloomberg wrote.

Tyler Durden Fri, 09/22/2023 - 10:15

Read More

Continue Reading

International

Michael Bloomberg puts up $500M to shut down this controversial industry

The businessman and former New York City mayor is investing big money for a high-powered campaign.

Published

on

Years ago, a rich person or company would indicate wealth by donating libraries and orphanages or traverse the world in bespoke yachts or aircraft.

You may commission a boat to extract an enemy submarine off the depths of the ocean floor. Perhaps you'd get an ivy league school of public policy and government named in your honor. If you were really industrious, you might even gather a bunch of your high-powered banker friends in a locked room on a distant island off the coast of Georgia to establish what we now call the Federal Reserve. 

DON'T MISS: China is no longer the leading exporter to U.S. (here's who is)

Nowadays, however, it's quite in vogue to gather large stockpiles of your cash and put it to work not for your people or your country. Billionaires think much bigger than that. If you're really rich, you put your money to work for the good of planet Earth. 

Take, for example, Microsoft  (MSFT) - Get Free Report and Amazon  (AMZN) - Get Free Report, who both recently pledged hundreds of millions of dollars between the two to capture carbon out of the atmosphere and dispose of it where it may no longer be accessed. 

Businessman and former New York City Mayor Michael Bloomberg is the latest billionaire to take a stab at the seemingly unsolvable climate crisis – and he's putting a vast sum of his money up to the challenge. 

Aerial view of Jon Amos Power plant shows smoke stacks and cooling, Coal, Poca, West Virginia. (Photo by: Visions of America/Joseph Sohm/Universal Images Group via Getty Images)

Joe Sohm/Visions of America/Getty Images

Michael Bloomberg pledges millions to fight coal

Bloomberg's charitable organization, Bloomberg Philanthropies, announced on Wednesday that it would front $500 million to shut down all existing coal plants in the U.S. and prevent future natural gas plants from being constructed. 

The pledge may sound anti-industrialist, but Bloomberg's "Beyond Carbon" initiative claims it will "turbocharge," environmental progress. 

The initiative includes the following bullet points: 

  • Finish the job on coal. With 372 of 530 coal plants announced to retire or closed to date – more than 70 percent of the country’s coal fleet – this next phase will shut down every last U.S. coal plant.
  • Slash gas plant capacity in half, and block all new gas plants.
  • Increase U.S. clean energy four-fold. Accelerate the clean energy transition to reach the goal of 80 percent of total electricity generation.

"Bloomberg Philanthropies has helped retire more than 70 percent of all U.S. coal plants, which accounts for more than 80 percent of all emissions reductions in the United States since 2010," Bloomberg, who's a special envoy on climate ambition and solutions to the U.N. proudly announced on Wednesday. 

Beyond Carbon will also fund the following organizations as a part of its mission toward progress: 

  • Earthjustice
  • Hip Hop Caucus
  • Sierra Club
  • RMI
  • League of Conservation Voters
  • Advanced Energy United
  • Coalfield Development

No stranger to controversy, Bloomberg has supported a number of divisive policies during his tenure in the public eye, including calls for banning polystyrene foam that is commercially known as Styrofoam, smoking, trans fats, and restricting sugary drinks in some public businesses. 

Now, it seems the billionaire is more concerned about climate change as a threat to public health than fat or soda. 

"This work has helped achieve more than 80 percent of all U.S. emissions reductions since 2010 and plant closures from the campaigns are estimated to have saved 49,900 lives, prevented nearly 77,500 heart attacks, and saved billions in healthcare costs," Bloomberg Philanthropies writes.

"But the U.S. is now at a pivotal moment — without rapid progress on clean energy, we will fail to meet our U.S. climate targets, and public health risks will skyrocket. Beyond Carbon’s next phase will ensure the U.S. delivers on our global climate commitments by retiring the last remaining coal plants, stopping the expansion of natural gas, and quadrupling clean energy capacity while continuing to prioritize environmental justice and workforce transition."

Read More

Continue Reading

International

New findings on hair loss in men

A receding hairline, a total loss of hair from the crown, and ultimately, the classical horseshoe-shaped pattern of baldness: Previous research into male…

Published

on

A receding hairline, a total loss of hair from the crown, and ultimately, the classical horseshoe-shaped pattern of baldness: Previous research into male pattern hair loss, also termed androgenetic alopecia, has implicated multiple common genetic variants. Human geneticists from the University Hospital of Bonn (UKB) and by the Transdisciplinary Research Unit “Life & Health” of the University of Bonn have now performed a systematic investigation of the extent to which rare genetic variants may also contribute to this disorder. For this purpose, they analyzed the genetic sequences of 72,469 male participants from the UK Biobank project. The analyses identified five significantly associated genes, and further corroborated genes implicated in previous research. The results have now been published in the prestigious scientific journal Nature Communications.

Credit: University Hospital Bonn / Katharina Wislsperger

A receding hairline, a total loss of hair from the crown, and ultimately, the classical horseshoe-shaped pattern of baldness: Previous research into male pattern hair loss, also termed androgenetic alopecia, has implicated multiple common genetic variants. Human geneticists from the University Hospital of Bonn (UKB) and by the Transdisciplinary Research Unit “Life & Health” of the University of Bonn have now performed a systematic investigation of the extent to which rare genetic variants may also contribute to this disorder. For this purpose, they analyzed the genetic sequences of 72,469 male participants from the UK Biobank project. The analyses identified five significantly associated genes, and further corroborated genes implicated in previous research. The results have now been published in the prestigious scientific journal Nature Communications.

Male-pattern hair loss is the most common form of hair loss in men, and is largely attributable to hereditary factors. Current treatment options and risk prediction are suboptimal, thus necessitating research into the genetic underpinnings of the condition. To date, studies worldwide have focused primarily on common genetic variants, and have implicated more than 350 genetic loci, in particular the androgen receptor gene, which is located on the maternally inherited X chromosome. In contrast, the contribution to this common condition of rare genetic variants has traditionally been assumed to be low. However, systematic analyses of rare variants have been lacking. “Such analyses are more challenging as they require large cohorts, and the genetic sequences must be captured base by base, e.g., through genome or exome sequencing of affected individuals,” explained first author Sabrina Henne, who is a doctoral student at the Institute of Human Genetics at the UKB and the University of Bonn. The statistical challenge lies in the fact that these rare genetic variants may be carried by very few, or even single, individuals. “That is why we apply gene-based analyses that first collapse variants on the basis of the genes in which they are located,” explained corresponding author PD Dr. Stefanie Heilmann-Heimbach, who is a research group leader at the Institute of Human Genetics at the UKB at the University of Bonn. Among other methods, the Bonn researchers used a type of sequence kernel association test (SKAT), which is a popular method for detecting associations with rare variants, as well as GenRisk, which is a method developed at the Institute of Genomic Statistics and Bioinformatics (IGSB) at the UKB and the University of Bonn.

Possible relevance of rare variants in male-pattern hair loss

The research involved the analysis of genetic sequences from 72,469 male UK Biobank participants. Within this extensive data set, Bonn geneticists, together with researchers from the IGSB and the Center for Human Genetics at the University Hospital Marburg, examined rare gene variants that occur in less than one percent of the population. Using modern bioinformatic and statistical methods, they found associations between male-pattern hair loss and rare genetic variants in the following five genes: EDA2R, WNT10A, HEPH, CEPT1, and EIF3F.

Prior to the analyses, EDA2R and WNT10A were already considered candidate genes, as based on previous analyses of common variants. “Our study provides further evidence that these two genes play a role, and that this occurs through both common and rare variants,” explained Dr. Stefanie Heilmann-Heimbach. Similarly, HEPH is located in a genetic region that has already been implicated by common variants, namely the EDA2R/Androgen receptor, which is a region that has consistently shown the strongest association with male-pattern hair loss in past association studies. “However, HEPH itself has never been considered as a candidate gene. Our study suggests that it may also play a role,” explained Sabrina Henne. “The genes CEPT1 and EIF3F are located in genetic regions that have not yet been associated with male-pattern hair loss. They are thus entirely new candidate genes, and we hypothesize that rare variants within these genes contribute to the genetic predisposition. HEPH, CEPT1, and EIF3F represent highly plausible new candidate genes, given their previously described role in hair development and growth.” Furthermore, the results of the study suggest that genes that are known to cause rare inherited diseases affecting both skin and hair (such as the ectodermal dysplasias) may also play a role in the development of male-pattern hair loss. The researchers hope that the puzzle pieces they have discovered will improve understanding of the causes of hair loss, and thus facilitate reliable risk prediction and improved treatment strategies.

The research was supported by funding from the Medical Faculty of the University of Bonn. Prof. Dr. Markus Nöthen, Director of the Institute of Human Genetics at UKB and co-author of the study, is a member of the Transdisciplinary Research Area (TRA) “Life and Health” at the University of Bonn. The publication costs in open access format were funded by the DEAL project of the University of Bonn.


Read More

Continue Reading

Trending